Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature

Yu, Dehong; Lü, Qing; Xie, Jing; Fang, Chao; Chen, Hongzhuan

doi:10.1016/j.biomaterials.2009.11.047

Cited by 164 publications

(102 citation statements)

References 38 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…So, mutation in KDR gene is therapeutically important and any association with clinical parameters or pathways can further help in embarking research focused on drugs targeting KDR. Intriguingly, KDR gene as a potential therapeutic target for angiogenesis inhibitor drugs has been reported previously [29][30][31].…”

Section: Discussionmentioning

confidence: 98%

KDR Mutation: A High-Frequency Rare Mutation and its Correlation with other Somatic Mutations in Indian Colorectal Cancer Patients

Jauhri¹,

Gupta²,

Shokeen³

et al. 2017

Next Generat Sequenc & Applic

View full text Add to dashboard Cite

Aim: This study aims to find out the frequency of KDR mutation in colorectal cancer patients and if any correlation exists between KDR mutation and demographical features or with other common and uncommon gene mutations occurring in colon cancer.Methods: FFPE samples of 112 patients were analyzed using next generation sequencing.Results: KDR gene was found to be mutated most frequently (19.6%) as compared to other uncommon gene mutations occurring among patients. 21/22 patients had the p.Q472H type of KDR mutation. It was significantly associated with mutations in PTEN (p=0.003), KRAS (p=0.026), APC (p=0.033), EGFR (p=0.036), NOTCH1 (p=0.029) and ERBB4 (p=0.008) mutations. More number of males (22.06%) harbored KDR mutations than the number of females (15.9%). A higher number of KDR mutations in Stage III (31%) as compared to other stages -I-II (19.23%) and IV (7.31%) was reported. KDR mutations were found to be in greater number in patients with lymph node metastasis (27.3%) as compared to liver metastasis (8%). However, a statistically significant association of any clinical parameter was not found. Conclusion:Our results suggest that although KDR is a rare somatic mutation in CRC, it plays a pivotal role in the development of colon cancer via angiogenesis pathway.

show abstract

Section: Discussionmentioning

confidence: 98%

KDR Mutation: A High-Frequency Rare Mutation and its Correlation with other Somatic Mutations in Indian Colorectal Cancer Patients

Jauhri¹,

Gupta²,

Shokeen³

et al. 2017

Next Generat Sequenc & Applic

View full text Add to dashboard Cite

show abstract

“…22 Briefly, a mixture of mPEG-PLA and DEX (6/1, w/w) was dissolved in 1 mL of dichloromethane solution. Next, 3 mL of sodium cholate solution (1%, w/v) was slowly poured into the solution and sonicated at 320 w for 30 seconds (Scientz Biotechnology Co, Ltd, Ningbo City, People's Republic of China).…”

Section: Methodsmentioning

confidence: 99%

“…Previously, our group developed a well-defined, nontoxic PEG-PLA stealth NP drug delivery system for chemotherapeutic agents. 22 Accordingly, we speculated that DEX-loaded PEG-PLA NPs (DEX-NPs) should facilitate sustained release of the drug, leading to a protection against cisplatin-induced hearing loss.…”

mentioning

confidence: 99%

A single dose of dexamethasone encapsulated in polyethylene glycol-coated polylactic acid nanoparticles attenuates cisplatin-induced hearing loss following round window membrane administration

Sun¹,

Wang²,

Zheng³

et al. 2015

IJN

View full text Add to dashboard Cite

This study aimed to investigate the sustained drug release properties and hearing protection effect of polyethylene glycol-coated polylactic acid (PEG-PLA) stealth nanoparticles loaded with dexamethasone (DEX). DEX was fabricated into PEG-PLA nanoparticles using an emulsion and evaporation technique, as previously reported. The DEX-loaded PEG-PLA nanoparticles (DEX-NPs) had a hydrodynamic diameter of 130±4.78 nm, and a zeta potential of −26.13±3.28 mV. The in vitro release of DEX from DEX-NPs lasted 24 days in phosphate buffered saline (pH 7.4), 5 days in artificial perilymph (pH 7.4), and 1 day in rat plasma. Coumarin 6-labeled NPs placed onto the round window membrane (RWM) of guinea pigs penetrated RWM quickly and accumulated to the organs of Corti, stria vascularis, and spiral ganglion cells after 1 hour of administration. The DEX-NPs locally applied onto the RWM of guinea pigs by a single-dose administration continuously released DEX in 48 hours, which was significantly longer than the free DEX that was cleared out within 12 hours after administration at the same dose. Further functional studies showed that locally administrated single-dose DEX-NPs effectively preserved outer hair cells in guinea pigs after cisplatin insult and thus significantly attenuated hearing loss at 4 kHz and 8 kHz frequencies when compared to the control of free DEX formulation. Histological analyses indicated that the administration of DEX-NPs did not induce local inflammatory responses. Therefore, prolonged delivery of DEX by PEG-PLA nanoparticles through local RWM diffusion (administration) significantly protected the hair cells and auditory function in guinea pigs from cisplatin toxicity, as determined at both histological and functional levels, suggesting the potential therapeutic benefits in clinical applications.

show abstract

“…Several TATs were conjugated to PLGA nanoparticulate systems to direct anticancer agents to tumors and to achieve brain drug delivery. 130,131 For example, Yu et al synthesized the aldehyde-PEG-PLGA block copolymer, which was used to prepare nanoparticles loaded with paclitaxel. 130 Using the N-terminal PEGylation technique, a K237 peptide (HTMYYHHYQHHL) was linked to the aldehyde group of PLGA-PEG nanoparticles.…”

Section: Peptide-functional Plga Nanoparticulatesmentioning

confidence: 99%

“…130,131 For example, Yu et al synthesized the aldehyde-PEG-PLGA block copolymer, which was used to prepare nanoparticles loaded with paclitaxel. 130 Using the N-terminal PEGylation technique, a K237 peptide (HTMYYHHYQHHL) was linked to the aldehyde group of PLGA-PEG nanoparticles. (The K237 peptide binds specifically to the kinase insert domain receptor [KDR] receptors that were predominantly expressed on the surface of tumor neovasculature, thereby suppressing the vascular endothelial growth factor [VEGF]-KDR angiogenic signal pathway.)…”

Section: Peptide-functional Plga Nanoparticulatesmentioning

confidence: 99%

Concepts and practices used to develop functional PLGA-based nanoparticulate systems

Sah¹,

Thoma²,

Desu³

et al. 2013

IJN

198

127

View full text Add to dashboard Cite

Abstract:The functionality of bare polylactide-co-glycolide (PLGA) nanoparticles is limited to drug depot or drug solubilization in their hard cores. They have inherent weaknesses as a drug-delivery system. For instance, when administered intravenously, the nanoparticles undergo rapid clearance from systemic circulation before reaching the site of action. Furthermore, plain PLGA nanoparticles cannot distinguish between different cell types. Recent research shows that surface functionalization of nanoparticles and development of new nanoparticulate dosage forms help overcome these delivery challenges and improve in vivo performance. Immense research efforts have propelled the development of diverse functional PLGA-based nanoparticulate delivery systems. Representative examples include PEGylated micelles/nanoparticles (PEG, polyethylene glycol), polyplexes, polymersomes, core-shelltype lipid-PLGA hybrids, cell-PLGA hybrids, receptor-specific ligand-PLGA conjugates, and theranostics. Each PLGA-based nanoparticulate dosage form has specific features that distinguish it from other nanoparticulate systems. This review focuses on fundamental concepts and practices that are used in the development of various functional nanoparticulate dosage forms. We describe how the attributes of these functional nanoparticulate forms might contribute to achievement of desired therapeutic effects that are not attainable using conventional therapies. Functional PLGA-based nanoparticulate systems are expected to deliver chemotherapeutic, diagnostic, and imaging agents in a highly selective and effective manner.

show abstract

Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature

Cited by 164 publications

References 38 publications

KDR Mutation: A High-Frequency Rare Mutation and its Correlation with other Somatic Mutations in Indian Colorectal Cancer Patients

KDR Mutation: A High-Frequency Rare Mutation and its Correlation with other Somatic Mutations in Indian Colorectal Cancer Patients

A single dose of dexamethasone encapsulated in polyethylene glycol-coated polylactic acid nanoparticles attenuates cisplatin-induced hearing loss following round window membrane administration

Concepts and practices used to develop functional PLGA-based nanoparticulate systems

Contact Info

Product

Resources

About